|
Salukhov V.V., Shustov S.B., Petrankov K.V.
Advantages of combined use of sodium-glucose co-transporter type 2 inhibitors and glucagon-like peptide-1 receptor agonists relatively to cardiovascular and renal outcomes in patients with type 2 diabetes mellitus
|
№8 / 2024
|
|
Bilevich O.A., Loginova E.N., Druk I.V., Chernykh D.A.
Prevalence of chronic kidney disease in the countries worldwide
|
№7 / 2024
|
|
Shchemeleva E.V., Skorodumova E.A.
Febuxostat: Efficacy and safety of the drug, prospects for application (literature review)
|
№5 / 2024
|
|
Mazurov V.I., Drapkina O.M., Martynov А.I., Sayganov S.А., Bashkinov R.A., Gaydukova I.Z., Sapozhnikov K.V., Tolkacheva D.G., Sableva N.A., Tsinserling А.Yu.
Meta-analysis of observational cohort studies on the relationships of asymptomatic hyperuricemia with chronic kidney disease
|
№10 / 2023
|
|
Demidova T.Yu., Izmaylova M.Ya., Antsiferov M.B.
Possibilities of early diagnosis of chronic heart failure and chronic kidney disease in patients with type 2 diabetes mellitus at the hospital stage
|
№9 / 2023
|
|
Abysov A.S., Kichigin V.A., Savvateeva O.A.
COVID-19 pandemic and the state of kidney function
|
№7 / 2023
|
|
Mazurov V.I., Sayganov S.A., Bashkinov R.A., Sapozhnikov K.V., Gaydukova I.Z., Tolkacheva D.G., Sableva N.A., Inamova O.V., Petrova M.S., Zinserling А.Yu.
Effect of urate-lowering therapy on the progression of chronic kidney disease in patients with osteoarthritis and asymptomatic hyperuricemia
|
№7 / 2023
|
|
|
№3 (приложение) / 2023
|
|
|
№3 (приложение) / 2023
|
|
Gaydukova I.Z., Mazurov V.I., Inamova O.V., Zinserling A.Yu., Bashkinov R.A.
Increasing of glomeral filtration rate in the setting of serum uric acid normalization in high cardiovascular risk patients – clinical observations
|
№3 / 2023
|
|
Maksudova A.N., Khalfina T.N., Almukhametova A.I.
Patient with hyperuricemia and chronic kidney disease is at the doctor: Peculiarities of curation in accordance with Russian recommendations
|
№3 / 2023
|
|
Shutov A.M., Efremova E.V., Serov V.A.
Blockade of renin-angiotensin-aldosterone system in patients with chronic heart failure and chronic kidney disease
|
№3 / 2023
|
Русский
